RightFit
RecruitingPhase 2

Psilocybin Therapy for Depression in Parkinson's Disease

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years to 80 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Blood draws

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Clinical assessments, neuroimaging, non-invasive brain stimulation, and peripheral blood draws will be used to quantify changes in depression, other non-motor and motor symptoms of PD, quality of life, and selected neural and blood-based biomarkers at multiple time points."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether psilocybin therapy can help improve symptoms in people with Parkinson's disease and depression. It is for adults ages 40 to 80 who currently have symptoms of depression.

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Are 40 to 80 years old.
  • Are comfortable speaking and writing in English.
  • Have Parkinson's disease with no known cause, diagnosed by a neurologist (a brain and nerve doctor).
  • Have Parkinson's at stages 1 to 3 on the Hoehn and Yahr scale while medicine or deep brain stimulation is working to help movement symptoms.
  • Currently have symptoms of depression.
  • Can attend all visits at UCSF and all online visits.
  • Have a primary care doctor, neurologist, or psychiatrist who is actively managing or coordinating your care.

Who can't join

  • Have symptoms such as seeing or believing things that are not real, without knowing they are not real.
  • Have major problems with memory or thinking.
  • Regularly take medicines that may interact badly with psilocybin.
  • Have a health condition that study doctors decide makes joining unsafe or not possible.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Age 40 to 80 * Comfortable speaking and writing in English * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect) * Currently experiencing depressive symptoms * Able to attend all in-person visits at UCSF as well as virtual visits * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating Exclusion Criteria: * Psychotic symptoms involving loss of insight * Significant cognitive impairment * Regular use of medications that may have problematic interactions with psilocybin * A health condition that makes this study unsafe or unfeasible, determined by study physicians

Study sites (1)

CA